A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
收藏DataCite Commons2026-05-05 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011925/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and with non-FLC solid tumors and to assess the T-cell response.
提供机构：
Vivli
创建时间：
2025-11-04
